[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT04779918":3,"trial-entities:NCT04779918":194,"trial-summary:NCT04779918":199},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":24,"primary_purpose":25,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":37,"secondary_outcomes":46,"sex":63,"minimum_age":64,"maximum_age":65,"healthy_volunteers":66,"eligibility_criteria":67,"std_ages":71,"locations":74,"central_contacts":179,"overall_officials":188,"references":192,"see_also_links":193},"NCT04779918","TB.2020.01.01","Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh","A Prospective Study Evaluating the Clinical Outcomes of Ventral or Inguinal Hernias Treated Robotically With OviTex® Reinforced Tissue Matrix","RECRUITING","2029-12-30","2026-04","2026-05-05","2021-04-29","Tela Bio Inc","INDUSTRY",false,"This study is designed to evaluate the post-operative complications and hernia recurrence following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.","This study is intended to evaluate the post-operative complications and recurrence following the use of OviTex in ventral or inguinal hernias being treated robotically. It is a single-arm study and all subjects will receive OviTex.",[19,20],"Hernia, Ventral","Hernia, Inguinal",[22,23],"use of mesh","robotic hernia repair","INTERVENTIONAL","TREATMENT",[27],"NA",{"count":29,"type":30},160,"ESTIMATED",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36},"DEVICE","OviTex Reinforced Tissue Matrix","All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.",[34],[38,42],{"measure":39,"description":40,"timeFrame":41},"Early surgical site occurrences or wound related events","Incidence of early peri- and post-operative surgical site occurrences or wound related events noted at the hernia repair site","occurring within the first 3 months of the ventral or inguinal hernia repair",{"measure":43,"description":44,"timeFrame":45},"Early post-operative complications","Incidence of other early post-operative complications","occurring within the first 3 months of the ventral or inguinal hernia repair.",[47,51,55,59],{"measure":48,"description":49,"timeFrame":50},"Late surgical site occurrences or wound related events","Incidence of late post-operative surgical site occurrences or wound related events noted at the hernia repair site","occurring > 3 months after index surgery",{"measure":52,"description":53,"timeFrame":54},"Late post-operative complications","Incidence of other late post-operative complications","occurring > 3 months after index surgery.",{"measure":56,"description":57,"timeFrame":58},"Patient Reported Outcomes","Patient Reported Outcomes (QoL and pain assessments)","Assessed at day 30, day 90, 12 months, and 24 months post-op",{"measure":60,"description":61,"timeFrame":62},"Hernia Recurrence","True hernia recurrence at the site of surgery","at post-operative day 90 and months 12 and 24","ALL","21 Years",null,true,{"inclusion":68,"exclusion":69,"raw_text":70},[],[],"Inclusion Criteria:\n\n1. Subject suffers from a ventral or inguinal hernia that requires surgical repair with the use of an implant to reinforce or replace weakened or missing tissue.\n2. The patient is scheduled for an elective robotic approach with the use of OviTex LPR, OviTex Core Permanent, OviTex 1S Permanent, or OviTex IHR.\n3. The size of the implant needed for repair is expected to be less than or equal to 15 x 25 cm for OviTex LPR and 25 x 40 cm for OviTex Core Permanent and OviTex 1S Permanent, with no size limitation for OviTex IHR.\n4. Subject meets CDC\u002FSSI Wound Classification Class I (Clean), Class II (Clean-Contaminated) or Class III (Contaminated) criteria.\n5. Subject is willing and able to sign an informed consent for the study and has signed the IRB approved Informed Consent form for this study.\n6. Subject is able to complete Quality of Life (QoL) and pain questionnaires.\n7. Subject is at least 21 years old.\n8. Subject is willing to comply and able to participate fully in, and for the full duration of, the study including follow-up requirements.\n\nExclusion Criteria at Baseline:\n\n1. Subject has a BMI of \\> 40\n2. Subject meets CDC\u002FSSI Wound Classification Class IV (Dirty-Infected) criteria\n3. Subject is female and is pregnant or plans to become pregnant during the course of the study.\n4. Subject has a life expectancy of \\\u003C 2 years making it unlikely that the subject will successfully achieve two-year follow-up.\n5. Subject has recent history of drug or alcohol abuse (in last 3 years).\n6. Subject has an allergy to ovine-derived products.\n7. Subject has participated in another clinical trial within the past 30 days or is currently involved in another clinical trial.\n8. Subject has a strangulated hernia.\n\nExclusion Criteria Intraoperative:\n\n1. Subject requires implant that cannot be introduced into the surgical site during the procedure via port or an existing incision.\n2. Subject unable to receive OviTex LPR, OviTex Core Permanent, OviTex 1S Permanent, or OviTex IHR at time of surgery.",[72,73],"ADULT","OLDER_ADULT",[75,93,102,111,118,126,141,155,164,171],{"facility":76,"status":8,"city":77,"state":78,"zip":79,"country":80,"contacts":81,"geoPoint":90},"University of South Alabama","Mobile","Alabama","36617","United States",[82,87],{"name":83,"role":84,"phone":85,"email":86},"Valrie Patterson, RN","CONTACT","251-445-9626","valriepatterson@health.southalabama.edu",{"name":88,"role":89},"Daniel McMahon, MD","PRINCIPAL_INVESTIGATOR",{"lat":91,"lon":92},30.69436,-88.04305,{"facility":94,"status":95,"city":96,"state":97,"zip":98,"country":80,"geoPoint":99},"SurgOne","ACTIVE_NOT_RECRUITING","Denver","Colorado","802210",{"lat":100,"lon":101},39.73915,-104.9847,{"facility":103,"status":104,"city":105,"state":106,"zip":107,"country":80,"geoPoint":108},"GenesisCare","TERMINATED","Destin","Florida","325541",{"lat":109,"lon":110},30.39353,-86.49578,{"facility":112,"status":104,"city":113,"state":106,"zip":114,"country":80,"geoPoint":115},"Surgical Healing Arts Center","Fort Myers","33912",{"lat":116,"lon":117},26.62168,-81.84059,{"facility":119,"status":95,"city":120,"state":121,"zip":122,"country":80,"geoPoint":123},"St. Luke's Hospital","Overland Park","Kansas","66213",{"lat":124,"lon":125},38.98223,-94.67079,{"facility":127,"status":8,"city":128,"state":129,"zip":130,"country":80,"contacts":131,"geoPoint":138},"University of Louisville","Louisville","Kentucky","40202",[132,136],{"name":133,"role":84,"phone":134,"email":135},"Dajana Nenadovic, RN","502-588-4571","dajana.nenadovic@uoflhealth.org",{"name":137,"role":89},"Farid Kehdy, MD",{"lat":139,"lon":140},38.25424,-85.75941,{"facility":142,"status":8,"city":143,"state":144,"zip":145,"country":80,"contacts":146,"geoPoint":152},"Munson Healthcare","Traverse City","Michigan","49684",[147,150],{"name":148,"role":84,"email":149},"Kelly VanSchouwen","kelly@researchtex.com",{"name":151,"role":89},"Joel Strehl, DO",{"lat":153,"lon":154},44.76306,-85.62063,{"facility":156,"status":157,"city":158,"state":159,"zip":160,"country":80,"geoPoint":161},"St. Francis Hospital","WITHDRAWN","Roslyn","New York","11576",{"lat":162,"lon":163},40.79982,-73.65096,{"facility":165,"status":157,"city":166,"state":159,"zip":167,"country":80,"geoPoint":168},"Mohawk Valley Health System","Utica","13502",{"lat":169,"lon":170},43.1009,-75.23266,{"facility":172,"status":95,"city":173,"state":174,"zip":175,"country":80,"geoPoint":176},"Houston Methodist","Houston","Texas","77030",{"lat":177,"lon":178},29.76328,-95.36327,[180,184],{"name":181,"role":84,"phone":182,"email":183},"Melissa LaMantia","757-761-4922","mlamantia@telabio.com",{"name":185,"role":84,"phone":186,"email":187},"Danielle Campbell","717-676-2589","dcampbell@telabio.com",[189],{"name":190,"affiliation":191,"role":89},"Geoffrey Slayden, MD","St. Lukes Hospital",[],[],{"nct_id":4,"conditions":195,"biomarkers":198},[196,197],"Inguinal Hernia","Ventral Hernia",[],{"nct_id":4,"found":66,"summary":200,"prompt_version":210},{"design":201,"status":202,"heading":203,"summary":204,"follow_up":205,"word_count":206,"commitments":207,"compensation":208,"drugs_mentioned":209},"This is a single-arm study, meaning all 160 participants will receive the OviTex device. There is no specified phase for this interventional study.","completed","Robotic Hernia Repair with OviTex Mesh","This study is looking at how well OviTex Reinforced Tissue Matrix works when used to repair ventral or inguinal hernias (a bulge caused by an organ pushing through a weak spot in muscle or tissue) using robotic surgery. All participants will receive OviTex during their hernia repair. Researchers will be watching for any surgical site issues or complications that happen within the first three months after surgery. You may be able to join if you are at least 21 years old, have a ventral or inguinal hernia needing surgical repair, and are scheduled for a robotic repair using OviTex. The study aims to enroll up to 160 people. The current recruitment status is unclear.","Participants will be followed for early surgical site occurrences and post-operative complications within the first three months after surgery.",114,"Not specified in the trial record.","Not stated in the trial record.",[34],"v2"]